The Neuromuscular Effect of Rocuronium in Patient
14. februar 2016 opdateret af: Go Eun Bae
The Neuromuscular Effect of Rocuronium in Patient Measuring Muscle Mass by Bioelectrical Impedance Analysis
Rocuronium block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles.
There have been several studies reported positive relationship between muscle mass and amount of neuromuscular junction.
The purpose of this study is to find 50% effective dose and 95% effective dose of rocuronium according to muscle mass.
Studieoversigt
Detaljeret beskrivelse
Rocuronium block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles.
There have been several studies reported positive relationship between muscle mass and amount of neuromuscular junction.
Until now, dose of rocuronium has been judged by patient's weight and height.
When the rocuronium was developed, 50% effective dose and 95% effective dose of rocuronium was calculated by patient corrected body weight which used weight and height.
However, height and weight do not represent exact muscle mass.
The purpose of this study is to find 50% effective dose and 95% effective dose of rocuronium according to muscle mass.
Measurement of muscle mass will be obtained using bioelectrical impedence analysis.
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
80
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Seoul, Korea, Republikken, 02841
- Rekruttering
- Korea University Anam Hospital
-
Kontakt:
- Goeun Bae, M.D.
- Telefonnummer: 8229205632
- E-mail: bgecs@naver.com
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
19 år til 64 år (Voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- All patient who undergo general anesthesia
Exclusion Criteria:
- Liver and kidney disease
- Any types of muscle disorder.
- Metal materials or pacemaker in body
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: rocuronium 1
Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.24mg per muscle mass(kg).
|
Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.
The individual dose method was used for the determination of the dose response of rocuronium.
After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))
Andre navne:
|
|
Eksperimentel: rocuronium 2
Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.32mg per muscle mass(kg).
|
Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.
The individual dose method was used for the determination of the dose response of rocuronium.
After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))
Andre navne:
|
|
Eksperimentel: rocuronium 3
Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.40mg per muscle mass(kg).
|
Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.
The individual dose method was used for the determination of the dose response of rocuronium.
After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))
Andre navne:
|
|
Eksperimentel: rocuronium 4
Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.48mg per muscle mass(kg).
|
Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.
The individual dose method was used for the determination of the dose response of rocuronium.
After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
percentage of neuromuscular block
Tidsramme: ten minutes
|
percentage of neuromuscular block is calculated by ratio of T1 to T4. T1 is result of first stimulation and T4 is result of fourth stimulation which are obtained by commonly used neuromuscular monitoring device.
|
ten minutes
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
onset time
Tidsramme: ten minutes
|
time from the end of injection of rocuronium until the maximal depression of T1 which is result of first twitch
|
ten minutes
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
lag time
Tidsramme: ten minutes
|
time from the end of injection of rocuronium until the first depression of the twitch response
|
ten minutes
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Studieleder: Go eun Bae, M.D., Korea University Anam Hospital
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. februar 2016
Primær færdiggørelse (Forventet)
1. juli 2016
Studieafslutning (Forventet)
1. august 2016
Datoer for studieregistrering
Først indsendt
13. januar 2016
Først indsendt, der opfyldte QC-kriterier
13. januar 2016
Først opslået (Skøn)
15. januar 2016
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
17. februar 2016
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
14. februar 2016
Sidst verificeret
1. februar 2016
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- Inbody2
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .